Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Recent Scares Could Impede Chinese Generic Exports To U.S.

This article was originally published in PharmAsia News

Executive Summary

In light of the recent scare involving Chinese-produced heparin and other safety issues, the budding generics drug industry in China could face a tough sell in the United States. The head of the American drug standards-setting organization, U.S. Pharmacopeia, said the recent product-safety incidents should be of concern to U.S. regulators. But he and another pharmaceutical market expert noted China has the people with skills and drive to comply with good manufacturing practices, enough so to make them a dominant generics marketer to the United States. (Click here for more

You may also be interested in...



Teladoc Health Acquires Livongo In $18.5Bn Deal, Creating Virtual Care Giant

The merger between virtual care companies Teladoc and Livongo will offer individuals a wide range of tech-enabled care during a time when telehealth continues to grow.   

Regeneron Pipeline Progresses On Several Fronts Despite COVID-19 Focus

Regeneron's antibody cocktail for SARS-Cov-2 is largely in holding mode for now, but the company announced progress on other fronts including for Dupixent in COPD and the NGF inhibitor fasinumab.

Market Intel: Why Telehealth, Digital Therapies Will Provide Mental Health Support Beyond COVID-19 Crisis

In this second part of a two-part series focusing on mental health tech, Medtech Insight highlights behavioral digital health companies that have attracted investors’ attention. Part one focused on transcranial magnetic stimulation.

UsernamePublicRestriction

Register

MT125590

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel